GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Century Therapeutics
Century is a biotech company developing next-generation cell therapies. Its stock price is a venture bet that its induced pluripotent stem cell-based platform will offer more affordable and effective cancer treatment.
Share prices of companies in the market segment - Oncology cell gene therapy
Century Therapeutics is a biotech company developing universal ("allogeneic") cell therapy based on iPSCs for the treatment of cancer. We have categorized it under "Oncology: Cellular Therapy." The chart below shows how the market views the future of cell medicine.
Broad Market Index - GURU.Markets
Century Therapeutics is a biotech company developing a universal iPSC-based cell therapy for cancer. As a component of the GURU.Markets index, it is working on the future of cellular medicine. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
IPSC - Daily change in the company's share price Century Therapeutics
Century Therapeutics' daily stock price fluctuations reflect the extreme volatility inherent in cell therapy companies. This metric is a measure of sensitivity to preclinical and clinical trial data.
Daily change in the price of a set of shares in a market segment - Oncology cell gene therapy
Century Therapeutics, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with the performance of IPSC, a pioneer in cell therapy, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Century Therapeutics is a biotech company developing cell therapy based on induced pluripotent stem cells. The company's shares move at the pace of scientific discoveries. This high volatility is part of the dynamics of the entire biotech sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Century Therapeutics
Century Therapeutics' year-to-date performance is a story about developing cell therapy based on induced pluripotent stem cells (iPSCs). Its 12-month market cap is entirely dependent on clinical trial data. The success of its "off-the-shelf" platform could fundamentally change the landscape of cancer cell therapy.
Annual dynamics of market capitalization of the market segment - Oncology cell gene therapy
Century Therapeutics is a biotech company developing off-the-shelf iPSC-based cell therapies for cancer treatment. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its innovative platform and the significant risks involved.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
The ticker symbol IPSC belongs to Century Therapeutics. As a biotech company focused on cell therapy, Century's stock performance is entirely dependent on clinical trial results. Its chart isn't about economics, but rather about the binary outcomes of cutting-edge science and medicine, where one piece of news can change everything.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Century Therapeutics
Century Therapeutics is a biotech company developing iPSC-based cell therapies. Its monthly performance reflects progress in this cutting-edge, yet risky, field. Clinical trial data and news about its manufacturing platform are driving strong stock movements.
Monthly dynamics of market capitalization of the market segment - Oncology cell gene therapy
Century Therapeutics develops cell therapies based on induced pluripotent stem cells (iPSCs), enabling the creation of "off-the-shelf" universal cancer treatments. The chart below reflects the current state of the art in the cell and gene therapy sector.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Century Therapeutics develops "off-the-shelf" cancer therapies from stem cells. This is one of the most advanced and complex areas of biotechnology. The company's stock price reflects investors' faith in its unique scientific platform, not the state of the economy, and is a bet on a future revolution in oncology.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Century Therapeutics
Century Therapeutics is a biotech company working in the cutting-edge field of cell therapy. Its weekly stock price is highly volatile, driven by news of progress in its scientific research and early clinical trial data, reflecting the significant risks and potential of the technology.
Weekly dynamics of market capitalization of the market segment - Oncology cell gene therapy
Century Therapeutics is a biotech company working in the cutting-edge field of cell therapy. Its weekly stock price is highly volatile, driven by news of progress in its scientific research and early clinical trial data, reflecting the significant risks and potential of the technology.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Century, a biotech company, lives in a world of its own. Its performance is driven by news of scientific breakthroughs. A chart comparing the stock to the S&P 500 clearly demonstrates how shares can rise or fall on company-specific events, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
IPSC - Market capitalization of the company Century Therapeutics
Century Therapeutics' market capitalization tells the story of the cutting edge of cell therapy. The company develops "off-the-shelf" (allogeneic) iPSC-derived immune cells for cancer treatment. The chart reflects investors' faith in the potential of this platform, which could make cell therapy more accessible. Its dynamics are a bet on the future of oncology.
IPSC - Share of the company's market capitalization Century Therapeutics within the market segment - Oncology cell gene therapy
Century Therapeutics is a biotech company developing induced pluripotent stem cell (iPSC)-based cell therapies for cancer treatment. Its market capitalization reflects the potential of its breakthrough platform. The chart below illustrates the valuation volatility typical of biotech.
Market capitalization of the market segment - Oncology cell gene therapy
Century Therapeutics is a biopharmaceutical company developing cell therapies based on induced pluripotent stem cells (iPSCs). The chart below shows the overall market capitalization of the cell therapy sector. It reflects the future of medicine, where off-the-shelf cell products may become more accessible than personalized ones.
Market capitalization of all companies included in a broad market index - GURU.Markets
This graph shows the future of cell therapy. Century Therapeutics is developing "off-the-shelf" immune cells (iPSCs) for cancer treatment that don't require individual production for each patient. Their line is a bet that this technology will make cell therapy widespread and accessible.
Book value capitalization of the company, segment and market as a whole
IPSC - Book value capitalization of the company Century Therapeutics
Century Therapeutics' capital is its scientific platform for developing allogeneic (donor-derived) iPSC cell therapies for cancer treatment and its financial reserves. This represents cutting-edge scientific and production capital. The chart shows how the biotech company accumulates and expends vast resources to develop next-generation cell therapies.
IPSC - Share of the company's book capitalization Century Therapeutics within the market segment - Oncology cell gene therapy
Century Therapeutics is a company developing cell therapies based on iPSCs (induced pluripotent stem cells). Its assets include cutting-edge laboratories and manufacturing facilities. The chart shows the company's share of this nascent and complex physical infrastructure for "off-the-shelf" cell therapies.
Market segment balance sheet capitalization - Oncology cell gene therapy
Cell therapy development, as the BCap_Seg chart for biotech shows, is a capital-intensive niche. Century Therapeutics, in creating "off-the-shelf" drugs, must invest in complex and expensive manufacturing facilities. The chart helps us understand that its science requires a robust industrial base.
Book value of all companies included in the broad market index - GURU.Markets
Century Therapeutics' assets include cutting-edge laboratories and capital for developing stem cell therapies. Its book value reflects the financial and scientific foundation for developing future "living drugs" that can be produced on an industrial scale for the treatment of cancer.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Century Therapeutics
Century Therapeutics is developing advanced cell therapy (iPSC) for cancer treatment. The company's book value is negligible compared to the potential of its scientific platform. MvsBCap's chart is a bet on a technological revolution in oncology. Its valuation will reflect the hopes and risks associated with one of the most complex and promising fields in biotech.
Market to book capitalization ratio in a market segment - Oncology cell gene therapy
Century Therapeutics is a biotech company developing cell therapies from induced pluripotent stem cells. Its valuation is driven by the potential of its breakthrough platform. The chart reflects the high expectations of investors.
Market to book capitalization ratio for the market as a whole
Century Therapeutics is a pioneer in developing cell therapy from renewable sources (iPSCs) for cancer treatment. The company's value lies in this breakthrough scientific platform. Investors are buying not current assets, but the potential to change the very paradigm of cell therapy. The chart reflects these lofty expectations.
Debts of the company, segment and market as a whole
IPSC - Company debts Century Therapeutics
Century Therapeutics, a company at the forefront of cell-based cancer therapy, uses capital to fund its complex and expensive preclinical and clinical programs. Developing living cell-based drugs requires massive investments in research and manufacturing. This chart shows how the company is funding the development of next-generation medicine.
Market segment debts - Oncology cell gene therapy
Century Therapeutics develops cutting-edge cell therapies based on induced pluripotent stem cells (iPSCs) for the treatment of cancer. Creating such a complex platform is an extremely capital-intensive undertaking. The chart below shows how the company funds its breakthrough, yet highly expensive, research at the forefront of oncology.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Century Therapeutics
Century Therapeutics operates in the cutting-edge field of cancer cell therapy. This chart reflects its reliance on external funding to conduct groundbreaking, but extremely expensive, research. Its high debt underscores the company's reliance on scientific breakthroughs, failure of which could jeopardize its very existence.
Market segment debt to market segment book capitalization - Oncology cell gene therapy
Century Therapeutics develops cell therapy based on induced pluripotent stem cells for the treatment of cancer. The chart illustrates the debt burden in the cutting-edge gene and cell therapy sector. It provides insight into how the company's financial model is typical for pioneers working on the development of "off-the-shelf" oncology drugs.
Debt to book value of all companies in the market
Century Therapeutics is a pioneer in the development of allogeneic induced pluripotent stem cell (iPSC)-based cancer therapies. The chart shows the overall financial situation in the market. For a company operating at the forefront of science, access to large, long-term investments is critical, and this depends on market conditions.
P/E of the company, segment and market as a whole
P/E - Century Therapeutics
This chart of Century Therapeutics, a company working in the field of cell gene therapy, reflects investors' hopes for a medical revolution. The company's valuation in this chart is based not on profits, but on the potential of its platform to create universal "cell-based drugs" for the treatment of cancer.
P/E of the market segment - Oncology cell gene therapy
This chart shows the average P/E valuation for the cell gene therapy sector, where Century Therapeutics operates. The industry's valuation is based on future potential. The chart illustrates the overall level of expectations and provides context for understanding how revolutionary the market considers Century's platform, even compared to other biotechs.
P/E of the market as a whole
Century Therapeutics is a biotech company developing cell therapies based on induced pluripotent stem cells (iPSCs). This technology enables the creation of versatile, ready-to-use drugs. This chart illustrates the risk appetite in biotech. It helps understand whether the market believes Century's platform can revolutionize cell therapy and how its potential is assessed.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Century Therapeutics
Century Therapeutics is a pioneer in cell therapy, developing universal ("off-the-shelf") immuno-oncology therapies from stem cells. The company's valuation is a bet on this cutting-edge technology. This chart reflects analysts' belief in the company's ability to create effective and safe "off-the-shelf" cell-based cancer therapies.
%20P%2FE%20Century%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Century-Therapeutics&v=1772617647748 "Chart of the company's future (projected) P/E Century Therapeutics")
Future (projected) P/E of the market segment - Oncology cell gene therapy
Century Therapeutics is a biotech company developing off-the-shelf cell therapies based on induced pluripotent stem cells (iPSCs) for the treatment of cancer. This chart shows its future profitability expectations, allowing us to assess how highly the market values its breakthrough technology platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-cell-gene-therapy&v=1772617647761 "Future (projected) P/E graph of the market segment - Oncology cell gene therapy")
Future (projected) P/E of the market as a whole
Century Therapeutics is a pioneer in induced pluripotent stem cell (iPSC)-based cancer therapy. It's the technology of the future. This chart, reflecting overall market optimism, shows how willing investors are to fund fundamental scientific breakthroughs. For Century, access to capital directly depends on the market's faith in the future.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772617647834 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Century Therapeutics
Century Therapeutics is a biotech company developing induced pluripotent stem cell (iPSC)-based cell therapies for cancer treatment. Its finances reflect significant investments in cutting-edge science. This chart shows the capital burn on the path to creating ready-to-use cell products that could revolutionize oncology.
Profit of companies in the market segment - Oncology cell gene therapy
Century Therapeutics is a biotech company developing off-the-shelf (allogeneic) cell therapies based on iPSCs (induced pluripotent stem cells) for the treatment of cancer. This graph reflects the dynamics of the gene therapy sector, where the creation of universal cell products has the potential to revolutionize cancer treatment and make it more accessible.
Overall market profit
Century Therapeutics is developing cutting-edge cell therapy. Its success depends on scientific breakthroughs. But the overall economic situation, reflected in the chart, is important. During periods of growth, investors and large pharmaceutical companies are more willing to fund revolutionary but risky technological platforms.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Century Therapeutics
Century Therapeutics is a pioneer in developing universal, off-the-shelf cell therapies based on iPSCs for cancer treatment. This technology has the potential to make cell therapy more accessible. This chart summarizes analyst forecasts, betting on the success of this revolutionary platform and its future commercialization.
%20profit%20of%20the%20company%20Century%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Century-Therapeutics&v=1772617648105 "Graph of future (projected) profit of the company Century Therapeutics")
Future (predicted) profit of companies in the market segment - Oncology cell gene therapy
Century Therapeutics is a biotech company developing cell therapies based on induced pluripotent stem cells (iPSCs). This technology enables the creation of versatile, ready-to-use cancer treatments. This chart shows profitability forecasts for the biotech sector, reflecting interest in next-generation cell therapy platforms.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-cell-gene-therapy&v=1772617648161 "Graph of future (predicted) profits of companies in a market segment - Oncology cell gene therapy")
Future (predicted) profit of the market as a whole
Century Therapeutics operates in the cutting-edge field of cell therapy for cancer treatment. It's a capital-intensive business, dependent on the investment climate. This chart, showing company expectations for future profits, indirectly reflects the availability of capital to fund long-term scientific research, which has the potential to transform medicine but requires significant investment.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772617648205 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Century Therapeutics
Century Therapeutics is a cancer cell therapy company. This chart reflects confidence in its cutting-edge scientific platform. For a biotech company without stable sales, its market value reflects the enormous potential of its treatments and the expectation of future clinical breakthroughs.
P/S market segment - Oncology cell gene therapy
Century Therapeutics develops anti-cancer drugs based on allogeneic (donor) stem cells. This chart reflects the average revenue estimate in the biotech sector. It allows us to estimate the premium investors are placing on the potential of Century's technology, which could make cell therapy more accessible and scalable than existing methods.
P/S of the market as a whole
Century Therapeutics is a biotech company developing a new generation of induced pluripotent stem cell (iPSC)-based cell therapies for cancer treatment. Their technology promises to create universal, off-the-shelf treatments. This chart, showing company valuations based on actual revenue, highlights the enormous expectations for breakthrough platforms like iPSC.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Century Therapeutics
Century Therapeutics develops anti-cancer drugs based on induced pluripotent stem cells (iPSCs). This chart reflects investors' confidence in the future of this cutting-edge technology. The valuation is based on the potential to create universal, "ready-to-use" cell therapies that could revolutionize cancer treatment.
%20P%2FS%20Century%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Century-Therapeutics&v=1772617648301 "The graph of the company's future (projected) P/S Century Therapeutics")
Future (projected) P/S of the market segment - Oncology cell gene therapy
Century Therapeutics is a biotech company developing cell therapies based on induced pluripotent stem cells (iPSCs) for the treatment of cancer. This technology has the potential to create universal, ready-to-use treatments. This chart shows how the market values this breakthrough approach compared to the gene and cell therapy sector.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-cell-gene-therapy&v=1772617648477 "Future (projected) P/S market segment graph - Oncology cell gene therapy")
Future (projected) P/S of the market as a whole
Century Therapeutics is developing cutting-edge cell therapy based on induced pluripotent stem cells (iPSCs) for the treatment of cancer. This schedule, reflecting investor appetite for breakthrough scientific platforms, is vital for Century. Market optimism is essential for funding such capital-intensive and long-term research that could transform oncology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772617648597 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Century Therapeutics
Century Therapeutics is a biotech company developing induced pluripotent stem cell (iPSC)-based cell therapies for cancer treatment. This chart reflects revenue from strategic alliances, not product sales. It shows the financial support for this cutting-edge platform, which promises to create "off-the-shelf" cell therapies.
Sales of companies in the market segment - Oncology cell gene therapy
Century Therapeutics is a biotechnology company developing next-generation cell therapies for cancer treatment based on induced pluripotent stem cells (iPSCs). Its operations are segmented into various programs for the treatment of hematological and solid tumors. This chart reflects the progress of one of these cutting-edge areas.
Overall market sales
Century Therapeutics is a biotechnology company developing in vitro cell therapy (iPSC) for cancer treatment. This technology has the potential to make cell therapy more accessible and scalable. The company's success hinges on a breakthrough in this complex scientific field and could revolutionize oncology, creating a huge new market.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Century Therapeutics
Century Therapeutics is a biotech company developing allogeneic (donor-derived) cell therapy based on induced pluripotent stem cells (iPSCs) for the treatment of cancer. Future sales projections are based on the company's bet that its platform will enable the creation of "off-the-shelf" cell therapies that will be more affordable than existing autologous therapies.
%20sales%20of%20the%20company%20Century%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Century-Therapeutics&v=1772617648964 "Schedule of future (projected) sales of the company Century Therapeutics")
Future (projected) sales of companies in the market segment - Oncology cell gene therapy
Century Therapeutics is developing induced pluripotent stem cell (iPSC)-based cell therapies for cancer treatment. This chart shows expectations for the cell and gene therapy sector. It reflects analysts' predictions of breakthroughs in the creation of "off-the-shelf" cell products, which could revolutionize the field of oncology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-cell-gene-therapy&v=1772617648989 "Schedule of future (projected) sales of companies in the market segment - Oncology cell gene therapy")
Future (projected) sales of the market as a whole
Century Therapeutics, a cell gene therapy company, operates at the cutting edge of science. Its development requires significant capital investment. This graph of total sales forecasts reflects the overall market condition and investor risk appetite, which is critical for funding such cutting-edge biotech startups.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772617649082 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Century Therapeutics
Century Therapeutics is a biotechnology company developing cutting-edge cell therapies based on induced pluripotent stem cells (iPSCs) for the treatment of cancer. This chart shows its financial performance at the R&D stage, where colossal investments in breakthrough science are the foundation for the creation of future commercially successful treatments.
Market segment marginality - Oncology cell gene therapy
Century Therapeutics develops anti-cancer cell therapies based on induced pluripotent stem cells (iPSCs). The strength of their platform lies in the potential to create "off-the-shelf" drugs. The chart demonstrates how competitive their operating model is in the complex and capital-intensive field of cell engineering.
Market marginality as a whole
Century Therapeutics is a biotechnology company developing induced pluripotent stem cell (iPSC)-based cell therapies for cancer treatment. This is a cutting-edge technology for "off-the-shelf" cell products. This graph shows the profitability of existing businesses, while iPSC's success depends on a breakthrough in the creation of universal cell-based therapies.
Employees in the company, segment and market as a whole
Number of employees in the company Century Therapeutics
Century Therapeutics is developing a new generation of cell therapy based on iPSC technology. This graph shows a team of highly skilled scientists working on one of the most challenging tasks in modern medicine. The size of this team is an indicator of the significant investment in creating "ready-to-use" cell-based therapies.
Share of the company's employees Century Therapeutics within the market segment - Oncology cell gene therapy
Century Therapeutics is a pioneer in the development of anti-cancer cell therapies based on induced pluripotent stem cells (iPSCs). This technology requires a world-class team of scientists. This chart demonstrates its leadership and depth in one of the most advanced and promising areas of oncology.
Number of employees in the market segment - Oncology cell gene therapy
Century Therapeutics is a biotechnology company developing cell therapies based on induced pluripotent stem cells (iPSCs). This chart reflects activity in the cell and gene therapy sector. The explosive growth of scientists in this cutting-edge field reflects the race to create "off-the-shelf" cell products, which is Century's goal.
Number of employees in the market as a whole
Century Therapeutics develops stem cell-based therapies. This is at the cutting edge of science. This graph reflects the current labor market, but Century is hiring exceptional specialists to create technologies that will transform medicine and the economy of the future, and its growth depends on investment in R&D.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Century Therapeutics (IPSC)
Century Therapeutics, Inc. is developing cell therapy based on induced pluripotent stem cells. This chart demonstrates the company's enormous market capitalization per employee. Investors value the revolutionary potential of the technology being developed by a small but unique team of scientists, rather than its current assets.
%20of%20the%20company%20Century%20Therapeutics%20(IPSC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Century-Therapeutics-IPSC&v=1772617649496 "Chart of market capitalization per employee (in thousands of dollars) of the company Century Therapeutics (IPSC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Century Therapeutics is a biotech company developing cell therapies based on induced pluripotent stem cells for the treatment of cancer. The cost per employee in this sector reflects the market valuation of a breakthrough scientific platform. It is an indicator of how much investors believe in the potential of their technology to transform approaches to cancer treatment.
%20by%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-cell-gene-therapy&v=1772617649564 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology cell gene therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Century Therapeutics is a biotech company developing cell therapies based on induced pluripotent stem cells (iPSCs) for the treatment of cancer. This is a cutting-edge scientific field. The chart reflects the enormous potential the market sees in the team's work creating "off-the-shelf" cell therapies.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772617649578 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Century Therapeutics (IPSC)
Century Therapeutics is a biotech company developing a new generation of cell therapy (iPSC-derived) for cancer treatment. This is highly complex and cutting-edge science. Currently, the company is not profitable. This negative graph shows how much capital is being burned for each scientist working on this futuristic R&D platform in the hopes of creating universal cell therapies.
%20Chart%20Century%20Therapeutics%20(IPSC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Century-Therapeutics-IPSC&v=1772617649594 "Company Profit Per Employee (in thousands of dollars) Chart Century Therapeutics (IPSC)")
Profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Century Therapeutics is a biotech company developing cell therapies based on induced pluripotent stem cells (iPSCs) for the treatment of cancer. This cutting-edge science requires elite specialists. This metric reflects the unique productivity of their team, allowing them to compare the effectiveness of their platform with industry standards in oncology.
%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-cell-gene-therapy&v=1772617649610 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Century Therapeutics is a biotech company developing cell therapies (iPSCs). This is one of the most advanced and complex sectors of biotech. The company is in the R&D stage. Its negative earnings per employee reflects the enormous investment in its scientific team, which is trying to create "test tube drugs" for cancer treatment.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772617649623 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Century Therapeutics (IPSC)
Century Therapeutics is a biotech company developing cell therapies based on induced pluripotent stem cells. Being in the research stage, it may not have stable revenue. This timeline will indicate whether its cutting-edge platform can lead to commercial success.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Century-Therapeutics-IPSC&v=1772617649686 "Sales chart per company employee Century Therapeutics (IPSC)")
Sales per employee in the market segment - Oncology cell gene therapy
Century Therapeutics is a biotech company developing off-the-shelf (allogeneic) CAR-T cell therapies from iPSCs (stem cells) for the treatment of cancer. This chart compares their revenue per employee (R&D) to the industry average, demonstrating how productive their advanced and sophisticated scientific platform is on the path to commercialization.
Sales per employee for the market as a whole
Century Therapeutics (IPSC) is a biotech company developing allogeneic cell therapies (iPSCs) for cancer treatment. This is at the cutting edge of science. The company is in the clinical stage and has no commercial sales revenue. This graph would reflect $0, which is the norm for R&D companies whose employees (scientists) are focused on development rather than sales.
Short shares by company, segment and market as a whole
Shares shorted by company Century Therapeutics (IPSC)
Century Therapeutics (IPSC) is a cell therapy company (iPSC) attempting to create "universal" CAR-T cells (from a donor, not from a patient). This is the "Holy Grail," but the technology is very complex and crude. This chart shows the number of skeptics who believe science isn't yet ready for such a breakthrough, and the company will burn through all its capital.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Century-Therapeutics-IPSC&v=1772617649858 "Short Shares Chart for the Company Century Therapeutics (IPSC)")
Shares shorted by market segment - Oncology cell gene therapy
Century Therapeutics is a biotech company developing off-the-shelf (allogeneic) cell therapies (iPSCs) for cancer treatment. This is the "holy grail" of cell therapy—creating a universal drug. This chart shows the odds against the iPSC therapy sector, reflecting the extreme skepticism of investors that this highly complex technology will work.
Shares shorted by the overall market
Century Therapeutics (IPSC) is a biotech company focused on cell therapy. It's one of the most cutting-edge and speculative technologies. When this market fear indicator rises, investors aren't willing to wait 10 years. They're selling off "research projects" without profits, like IPSC, en masse to cash out.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Century Therapeutics (IPSC)
Century Therapeutics is a biotech company developing off-the-shelf (iPSC) cell therapies for cancer. This is a cutting-edge but complex technology. This indicator measures investor excitement, showing when confidence in their platform is causing the stock to be overheated (above 70) or when trial delays are causing it to be oversold (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Century-Therapeutics-IPSC&v=1772617650123 "RSI 14 indicator chart for the company's stock Century Therapeutics (IPSC)")
RSI 14 Market Segment - Oncology cell gene therapy
Century Therapeutics is a biotech company developing "allogeneic" (from a donor) iPSC (iPSC-based) cell therapy for cancer treatment. This chart measures the collective excitement in the cell therapy sector. It helps determine whether the entire speculative segment is overheated by expectations.
RSI 14 for the overall market
For Century Therapeutics, a biotech in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IPSC (Century Therapeutics)
Century Therapeutics is a biotech company developing allogeneic (off-the-shelf) cell therapy (iPSC) for cancer treatment. This chart shows the average analyst forecast. Their targets are based on an assessment of the platform's potential, its manufacturing success, and data from early clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IPSC-Century-Therapeutics&v=1772617650348 "A chart showing analyst consensus forecasts for the expected stock price. IPSC (Century Therapeutics)")
The difference between the consensus estimate and the actual stock price IPSC (Century Therapeutics)
Century Therapeutics is a pioneer in the field of "universal" cell therapy. The company develops "off-the-shelf" (allogeneic) oncology drugs from iPSC cells. This chart measures the gap between the current price and the consensus target price. It demonstrates the enormous, yet risky, potential analysts see in this futuristic R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IPSC-Century-Therapeutics&v=1772617650375 "A chart showing the difference between the consensus forecast and the actual stock price. IPSC (Century Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology cell gene therapy
Century Therapeutics is a biotech company developing off-the-shelf cell therapies (iPSCs) for cancer treatment. This chart shows the general expectations of oncology analysts. It reflects whether experts believe in the future of "universal" cancer cell therapy.
Analysts' consensus forecast for the overall market share price
Century Therapeutics is a biotech company developing "off-the-shelf" (allogeneic) cell therapies (iNK, iT) for cancer treatment. This is one of the most advanced and expensive areas of medicine. This chart shows the overall "risk appetite" in the market. For Century, whose value is an option on a future scientific breakthrough, overall market optimism (risk appetite) is critical to funding multi-year R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Century Therapeutics
Century is a pioneer in universal cell therapy. They use iPSC (stem cell) technology to generate standard (off-the-shelf) immune cells for cancer treatment, rather than personalized ones. This graph is a clear indicator of faith in their deep science. It reflects their R&D progress and the market's belief that their industrial approach to CAR-T therapy will one day be victorious.
AKIMA Market Segment Index - Oncology cell gene therapy
Century Therapeutics (IPSC) is at the forefront of oncology, developing allogeneic (off-the-shelf) cell therapies based on iPSCs. Their goal is to create scalable cancer treatments. This chart shows the average index value for the cell and gene therapy segment. It allows investors to assess how Century's platform is perceived by the market relative to the collective risks and prospects of its competitors.
The AKIM Index for the overall market
Century Therapeutics is a biotech company developing allogeneic cell therapies (iNK and iT) based on iPSCs for the treatment of cancer. This chart, reflecting the market average, is an indicator of risk appetite. It provides a macro backdrop that is critical for assessing the prospects of this advanced cell engineering platform.
